Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 12/20 | 0.48 |
| ▸ | CDK4 | P11802 | 1/20 | 0.48 |
| ▸ | CCND1 | P24385 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 12/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3405972 | 0.89 | OPRL1 (0.60) | OPRL1CDK4OPRM1SLC6A4HTR1A | |
| SCHEMBL4110049 | 0.87 | OPRM1 (0.63) | OPRL1OPRM1SLC6A4HTR1AMPO | |
| SCHEMBL3432646 | 0.80 | SLC6A4 (0.49) | MAPTOPRL1OPRM1SLC6A4HTR1A | |
| SCHEMBL3412042 | 0.79 | OPRM1 (0.49) | OPRL1OPRM1OGFRL1HTR2AHTR2C | |
| SCHEMBL3412128 | 0.77 | HTR6 (0.52) | OPRL1OPRM1SLC6A4 | |
| SCHEMBL2378734 | 0.75 | MAPT (0.55) | MAPTOPRL1CDK4CCND1OPRM1 | |
| SCHEMBL2379116 | 0.75 | MAPT (0.60) | MAPTOPRL1CDK4CCND1OPRM1 | |
| SCHEMBL3433096 | 0.74 | SLC6A4 (0.52) | OPRL1CDK4CCND1OPRM1SLC6A4 | |
| Hydrochloric Acid SCHEMBL303144 | 0.74 | MAPT (0.55) | MAPTOPRL1CDK4CCND1OPRM1 | |
| Hydrochloric Acid SCHEMBL2379937 | 0.74 | MAPT (0.59) | MAPTOPRL1CDK4CCND1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288430-B2 | Spiro(5.5)undecane derivatives | GRUNENTHAL GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| EP-2257526-B1 | SPIRO(5.5)UNDECANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2011-12-14 | — | — | EP | disclosed |
| US-20090247505-A1 | SPIRO(5.5)UNDECANE DERIVATIVES | GRUNENTHAL GMBH (DE) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247505-A1 | SPIRO(5.5)UNDECANE DERIVATIVES | OPRL1, OPRD1, OPRM1 | MAPT 1221/4885OPRL1 1/4885CDK4 2301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.